News Archive

Johnson & Johnson and Sanofi are using IBM Watson’s computer brain/big data cruncher to support research and development. It will be used to identify new applications for drugs that have already been developed and to leaf through scientific papers that detail clinical trial outcomes, according to a statement from IBM. The partnerships follow a new development in Watson’s evolution that help it visually uncover patterns and pinpoint connections in related data to accelerate the discovery process and advance science research.

“Watson now has the ability to understand the language of chemistry, biology, legal and intellectual property, giving scientists the ability to make connections with data that others don’t see, which can lead to rapid breakthrough in discoveries,” the statement said.

Every day our DNA breaks a little. Special enzymes keep our genome intact while we’re alive, but after death, once the oxygen runs out, there is no more repair. Chemical damage accumulates, and decomposition brings its own kind of collapse: membranes dissolve, enzymes leak, and bacteria multiply. How long until DNA disappears altogether? Since the delicate molecule was discovered, most scientists had assumed that the DNA of the dead was rapidly and irretrievably lost. When Svante Pääbo, now the director of the Max Planck Institute for Evolutionary Anthropology in Germany, first considered the question more than three decades ago, he dared to wonder if it might last beyond a few days or weeks. But Pääbo and other scientists have now shown that if only a few of the trillions of cells in a body escape destruction, a genome may survive for tens of thousands of years.

The crossover round is alive and well. Just a few days after Dermira put out the word that a consortium of backers had come up with a $51 million C round, the company rolled out a $75 million IPO. And the news, along with a fresh, $86 million filing from Rhythm Pharmaceuticals, helps set the stage for a new round of fall biotech IPOs that will once again test investors’ appetite for risk.

First, let’s look at Redwood City, CA-based Dermira. Focused on skin ailments, the biotech is partnered with UCB on the development of Cimzia–already on the market–for psoriasis, a field that will soon be packed with a host of contenders from the likes of Novartis ($NVS) and Eli Lilly ($LLY). The biotech has laid plans for a Phase III psoriasis trial in 2015 as it pursues further work on a new therapy for “hyperhidrosis,” or excessive sweating, in the armpits. It’s in a Phase IIb study and a successful outcome would set the stage for a late-stage program. There’s also an acne treatment in early mid-stage studies.

Mayor Stephanie Rawlings-Blake on Thursday appointed six new members to the Baltimore Development Corp. board, an announcement that comes as Councilman Bill Cole takes over as president of the agency.

The six new members are mostly long-standing vacancies on the 19-member board. One of the appointments fills a seat opened after city Finance Director Harry Black announced last month that he was leaving his job to become city manager in Cincinnati.

Scientists who use government money to conduct genomic research will now be required to quickly share the data they gather under a policy announced on Wednesday by the National Institutes of Health.

The data-sharing policy, which will take effect with grants awarded in January, will give agency-financed researchers six months to load any genomic data they collect—from human or nonhuman subjects—into a government-established database or a recognized alternative.

The National Science Foundation (NSF) announced today that it will provide a multi-million dollar grant to create a hub of innovation that unites public and private institutions throughout Southern California, headquartered at and administered by the University of Southern California, the California Institute of Technology (Caltech), and the University of California Los Angeles.

The new center is part of the NSF Innovation Corps, or “I-Corps,” initiative, which is aimed at fostering innovation throughout the U.S. by encouraging the translation of ideas and research beyond the laboratory to create social and economic impact. The announcement cements the position of Southern California as a crucial focal point of technology entrepreneurship in the country.

The Maryland Department of Business and Economic Development says its Maryland Venture Fund has made follow-on investments in two Maryland startups totaling $700,000.

Bethesda-based KoolSpan, a mobile security encryption company, received $400,000. BrainScope, also in Bethesda, got $300,000. BrainScope is developing neurotechnology for quickly assessing traumatic brain injury.

Over $21M in New Funding Available for Bioreactors for Reparative Medicine

Learn more at webinar on September 12, 3 pm ET

The National Heart, Lung, and Blood Institute (NHLBI), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), and the National Center for Advancing Translational Sciences (NCATS) announce a new program that aims to support multidisciplinary small business teams in the development of complex, three-dimensional engineering systems for growing heart, lung, or bone marrow tissue. Ultimately, bioreactor designs should provide the most physiologically relevant environment to promote correct 3-dimensional tissue growth and maintenance, which is also efficient, safe and economical. Such devices should be made commercially available and widely disseminated to researchers for application in the translational setting.

Baltimore is going to be OK, as long as it has its big name medical centers.

That’s the big takeaway from a new report by Moody’s Investors Service that looked at the economic impact large medical and education systems have on the cities where they are based.

Venture capital continued its love affair with biotechnology in the second quarter, with investment in biotech reaching record levels.

Venture capitalists invested $1.84 billion in 122 biotech deals in the period, according to a MoneyTree report released Monday by PricewaterhouseCoopers and the National Venture Capital Association, using Thomson Reuters data.